cute coronary syndromes (ACS) have a complex and heterogeneous pathophysiology, 1,2 with patients being at high risk of death and cardiac ischemic events. 3 Many pathophysiologic systems, such as thrombosis and inflammation, have been implicated in the formation and destabilization of the culprit atheromatous plaque. 4, 5 It is generally believed that plaque rupture is a consequence of progressive thinning of the fibrous cap caused by impaired collagen synthesis, 6 increased extracellular matrix degradation, 7 and decreased function and number of smooth muscle cells (SMC). 8 Macrophages within the atherosclerotic plaque are believed to have a major role in these processes by their generation of cytokines and release of matrix-degrading enzymes. 9 Factor VII activating protease (FSAP) is a plasma serine protease that is predominantly expressed in the liver. It has been identified as a protease that activates coagulation factor VII as well as pro-urokinase (pro-uPA). 10,11 FSAP also inactivates tissue factor pathway inhibitor (TFPI), which would also have a procoagulant effect on blood clotting. 12 More recently, various studies have supported the emerging role of FSAP in advanced atherosclerosis and cardiovascular diseases. [13] [14] [15] [16] [17] Next to hepatocytes, the major cellular source of intravascular FSAP is monocytes, the only blood cells capable of synthesizing FSAP in response to various inflammatory mediators such as cytokines and bacterial endotoxins. 13 FSAP expression is also enhanced by differentiation of human circulating monocytes into macrophages. FSAP accumulates in unstable coronary atherosclerotic plaques, but is only minimally expressed in stable PARAHULEVA MS et al.
plaques. 13 The protease expressed by the FSAP gene carrying the single nucleotide polymorphism (SNP) Marburg I (MI; G534E, 1601 G/A) has a reduced ability to activate pro-uPA and FVII, and inactivate TFPI. 12, 14 The MI-SNP was found to be an independent risk factor for the development of late complications of carotid stenosis 15 and may also be related to the occurrence of venous thromboembolism 16 and is associated with increased risk for stroke, 17 thus representing a general cardiovascular risk factor. 18 Recently, the measurement of circulating FSAP antigen and activity demonstrated a modest association between elevated FSAP concentration and venous thromboembolism. 19 We have shown that the concentrations of circulating FSAP in pregnancy and in women using oral contraceptives are increased, indicating that hormonal status critically influences FSAP expression. 20 Furthermore, SNPs in the FSAP gene are also linked to a higher incidence of venous thrombosis in the elderly. 21 FSAP also inhibits the activity of platelet-derived growth factor-BB (PDGF-BB) and this in turn influences remodeling processes in the vessel wall. 22 It is not known if the concentration of circulating FSAP or its activity is related in any way to the development and progression of coronary artery disease (CAD). This study was designed to examine the relationship between the plasma concentration and activity of FSAP and CAD, and to investigate FSAP expression in monocytes in patients with CAD. We also defined the precise role of circulating FSAP plasma levels for predicting endpoints such as death or non-fatal myocardial infarction in patients with ACS. Furthermore, we also compared the prognostic significance of FSAP plasma levels with markers of systemic inflammation, coagulation, and myocardial necrosis.
Methods

Study Population
This study was a single-center, prospective clinical trial and included 231 patients with chest pain and suspected CAD admitted to the Department of Internal Medicine I Cardiology/ Angiology, University Hospital of Giessen-Marburg from 2007 to 2008. The study was approved by the Ethics Committee of the University of Giessen and informed written consent was given by all patients. All patients underwent coronary angiography in the coronary care unit to detect abnormalities on ECG or any angina-like chest symptoms. 23 On the basis of their clinical characteristics, the patients were classified into 4 diagnostic groups: (1) stable angina pectoris (SAP, classes I-III according to the Canadian Cardiovascular Society classification, 23,24 (2) unstable angina pectoris (UAP, classes IIB-IIIB according to Braunwald's classification), 25-27 and (3) acute myocardial infarction (AMI) 26,28 and (4) the rest comprised a control group (ie, patients without coronary heart disease and with a normal coronary angiogram). Blood samples from control subjects were also obtained at the time of coronary angiography.
The SAP group comprised patients with typical effort anginal pain (<6 months) associated with documentation of inducible myocardial ischemia during exercise stress test, defined as ST-segment depression ≥0.1 mV on the ECG during bicycle ergometry, or hypo/akinesia of one or more segments of the cardiac wall during stress-echocardiography, that was relieved by rest or sublingual nitrates, or both. 23, 24 The patients in the SAP group had angiographically documented organic stenosis >50% in at least 1 major coronary artery. All patients with UAP had experienced ischemic chest pain at rest within the preceding 48 h or a sudden increase in episodes of a previously stable angina, but with no evidence of myocardial necrosis by enzymatic criteria. 25-27 For the AMI group, 87 consecutive patients were screened for inclusion into the study immediately after AMI diagnosed according to American College of Cardiology/American Heart Association (ACC/AHA) guidelines. 26, 28 The AMI group consisted of patients with non-ST-elevation myocardial infarction (NSTE-ACS) and ST-elevation myocardial infarction (STE-ACS) <6 h after the onset of symptoms. STE-ACS was diagnosed in patients with 30 min of continuous chest pain at rest, a new 2-mm ST-segment elevation in at least 2 contiguous ECG leads or (presumed) new left bundlebranch block, and elevation of biochemical markers (creatine kinase (CK), creatine kinase myoglobin binding (CK-MB) isoenzyme or troponin I). NSTE-ACS was diagnosed by chest pain and a positive cardiac biochemical marker without new ST-segment elevation. NSTE-ACS patients when compared with UAP patients had elevated biochemical markers of myocardial necrosis (elevated concentrations of troponin I). Standard procedures for the quantification of CK, CK-MB, and troponin I were used (high-sensitivity assays, Siemens Medical Solutions Diagnostics, Germany). Age, sex, body mass index (BMI), history of previous myocardial infarction, cardiovascular risk factors including systemic hypertension (systolic blood pressure >140 mmHg, diastolic blood pressure >90 mmHg, or receiving antihypertensive drugs), diabetes mellitus (fasting glucose concentration ≥126 mg/dl or random blood glucose concentration ≥200 mg/dl), current smoking habit, hyperlipidemia (total cholesterol concentration ≥240 mg/dl, fasting triglyceride concentration ≥150 mg/dl, or receiving hyperlipidemia medication), and a family history of CAD, as well as cardiac medications, were assessed and recorded at study entry.
Treatment of the patients was according to the hospital's standard routine following the guidelines for AMI with and without ST-segment elevation. Unfractionated heparin was administered until at least 1 h before percutaneous coronary intervention (PCI). Patients with UAP and AMI undergoing treatment by stent placement were compared with the patients with SAP undergoing the same treatment. Exclusion criteria were recent (<6 months) PCI, recent (<6 months) myocardial infarction, previous coronary artery bypass grafting (CABG), contraindications for PCI and/or only indication for CABG, body temperature >38.0°C, inflammatory disease (eg, infections, autoimmune diseases), malignancies, pregnancy or breastfeeding, recent major surgery, and unwillingness to provide written informed consent to participate.
Hematology
Peripheral blood samples were obtained by direct venipuncture and immediately transferred into EDTA and CTAD (citrate, theophylline, adenosine and dipyrimadole) tubes (Vacutainer, Becton Dickinson, Plymouth, UK) at the following time points: 1 day, 3 days, and 5 days after stenting. To obtain plasma, blood was centrifuged at 3,000 g for 20 min at room temperature, and the plasma frozen in aliquots and stored at −70°C until analysis. Routine blood chemistry and lipids (total cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides) were analyzed using fresh blood samples according to established enzymatic methods at the local laboratories (as described before).
FSAP Concentration and Activity
Total FSAP activity was measured by an established immunocapture activity test using a monoclonal antibody (mAb) against FSAP, exactly as described before. 28, 29 In detail, microtiter FSAP in ACS plates were coated with anti-FSAP mouse mAb 677 (American Diagnostica, Pfungstadt, Germany) and coating buffer. Diluted plasma probes were applied to the plate, which was incubated for 1 h at room temperature and then washed 3 times.
Recombinant scuPa (Saruplase, Grünenthal, Stolberg, Germany) and chromogenic substrate S-2444 (Haemochrome, Essen, Germany) were added and incubated (37°C) and the absorption at 405 nm was recorded with a microplate reader EL 808 (Biotek Instruments, Winooski, OR, USA). Calibration curves were established through dilution series of standard human plasma (SHP, Siemens Medical Solution and Diagnostics) and served as the reference for measured FSAP activity. The plasma activity in 1 ml SHP was defined as 1 plasma equivalent unit (PEU/ml).
Total FSAP concentration was detected by an FSAP-specific ELISA exactly as described before. 28, 29 Microtiter plates were coated with a rabbit polyclonal anti-FSAP Ab (American Diagnostica) and diluted patient plasma was then incubated for 1 h at room temperature. After extensive washing, anti-FSAP mAb 677 was added and incubated (60 min at room temperature). Detection was with peroxidase-coupled mouse Ab and 3,3′,5,5′-tetramethylbenzidin (TMB-Substrate-Kit, Pierce, Rockford, IL, USA). Optical density was measured at 405 nm and the FSAP concentration was quoted in μg/ml using SHP as a standard.
Monocytes Isolation and Cell Culture
Monocytes from all patients and non-CAD subjects were isolated with a RosetteSep ® -Kit according to the manufacturer's instructions.
RNA Isolation and Real-Time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
Total RNA was isolated using the RNeasy ® kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions, including DNase treatment. cDNA synthesis was performed using a kit from Perkin Elmer as described previously 13 and the cDNA was stored at −20°C. Relative mRNA quantification was performed by real-time RT-PCR using a CFX 96 real-time system (Bio-Rad, Munich, Germany). For FSAP, the following primer sequences were used: sense: CCCACTGAGCCAT-CAACCAA; antisense: TGGGGCATGGAGATGGTC with a product size of 169bp. The expression was normalized to the internal control (GAPDH) sense: CCT CAA GAT CAT CAG CAA TGC CTC CT; antisense: GGT CAT GAG TCC TTC CAC GAT ACC AA) and relative to the expression in control group, was calculated. Reference indicates age- and sex-matched normal reference group; smoking, percentage of subject with a history of smoking within the past 6 months; diabetes mellitus, percentage of subjects with ongoing treatment for diabetes mellitus or having a fasting blood glucose ≥126 mg/dl; hypertension, percentage of subjects with a systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg. AMI, acute myocardial infarction; ACE, angiotensin-converting enzyme; CAD, coronary artery disease; FSAP, factor VII activating protease; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; PEU, plasma equivalent unit; SAP, stable angina pectoris; UAP, unstable angina pectoris. PARAHULEVA MS et al.
Determination of MI-SNP
Genomic DNA was prepared from frozen whole blood with the GenomicPrep blood DNA isolation kit (Amersham Pharmacia Biotech, Vienna, Austria) and DNA analysis was performed as described previously. 30,31
Patient Follow-up Patients were followed up for 12 months by outpatient clinic attendance, telephone contact, and review of their medical notes. We defined 'adverse endpoints' as cardiovascular death (death in the context of ischemic or other heart disease, or unexplained death, presumed cardiac), recurrent ACS (new episode of ACS requiring hospital admission), non-elective revascularization (emergency or urgent revascularization in the context of new hospital admission) and/or admission for acute heart failure.
Complete follow-up data were available for 169 patients (93.9%) with CAD (SAP, UAP, and AMI). Information from the other 6.1% of the patients was not available because the patients were not contactable. To dichotomize the study population according to an optimal threshold concentration, receiver-operating characteristic curves were constructed to assess the sensitivity and specificity throughout the concentration and activity of FSAP and analysis over the dynamic range of the FSAP assay was used to identify the threshold concentration for FSAP providing the highest predictive value. In order to test our main hypothesis that coronary diagnostic group has a significant effect on survival rates, we produced Kaplan-Maier plots and applied a Cox regression with coronary diagnostic group as a categorical co-variate. Patients with SAP, UAP or AMI (NSTE-ACS and STE-ACS) were included for the Kaplan-Meier analysis. In addition we applied a Cox proportional hazard model with multivariate adjustments. All hypothesis was 2-tailed, and P≤0.05 was considered statistically significant. All statistical calculations were performed using the statistical package SPSS for Windows 17.0.1 (SPSS Inc, Chicago, IL, USA).
Statistical Analysis
Results
Plasma FSAP Level and Activity in Patients With CAD
The clinical characteristics of the study population are listed in Table 1 . There were no significant differences between the SAP, UAP or AMI group and the control group in the following categories: age, sex, incidence of diabetes mellitus or adipositas, concentrations of total cholesterol, HDL cholesterol, low-density lipoprotein cholesterol, and triglycerides. The percentage of active smokers was similar in all groups, but the percentage of patients with hypertension and those with high concentrations of troponin I, CK, and CK-MB was significantly higher in patients in the SAP, UAP and AMI groups compared with the control group. We measured FSAP (concentration and activity) in patients with ACS (AMI and UAP) and in those in a stable condition (patients with SAP and controls) (Figure 1) . Comparisons between groups were analyzed by general linear model and the differences among the groups were as follows: the median FSAP concentration in the control subjects was not significantly different from that in patients with SAP or UAP, or in patients with AMI ( Figure 1A) . On the other hand, plasma FSAP activity (PEU/ml) in patients with UAP and AMI was significantly above the range of the control population ( Figure 1B) . FSAP activity levels increased significantly in patients with SAP and reached maximum levels in patients with AMI ( Figure 1B) . Multiple-regression models showed that the FSAP concentration was not associated with age, sex, or risk factors ( Table 2 ).
In the cluster of 169 patients with SAP, UAP and AMI, 9 subjects were heterozygous for the FSAP MI-SNP, corresponding to a carriage rate of 5.3%. This study was not designed to study the association of MI polymorphism with the survival of ACS patients. Further epidemiological studies are required to 
Time Course of Changes in FSAP Concentration and Activity in Patients With ACS (UAP and AMI)
Plasma FSAP concentration and activity in the course of ACS (UAP and AMI) increased significantly throughout the acute phase after coronary intervention, attaining a peak level after 72 h (Figure 2A) . Plasma FSAP activity (PEU/ml) was significantly higher in patients with ACS at all time points examined compared with admission ( Figure 2B) . FSAP activity levels peaked 3 days after admission and gradually decreased afterward. At 5 days, the FSAP concentration and activity level had declined progressively, but were still above the range of FSAP activity on the day of admission. The number of patients studied at day 0 (n=87) was much higher that the number of patients studied at day 1 (n=55), 3 (n=50) and 5 (n=49), respectively, because not all patients were available on the days following admission.
FSAP Gene Expression in Monocytes From Patients With ACS (UAP and AMI) and Control Subjects
To examine the expression pattern of FSAP in monocytes after inflammatory stimulation in vivo, we next examined the concentrations of FSAP mRNA in monocytes from patients with ACS (UAP and AMI, n=130) undergoing PCI. This procedure, representing mechanical plaque rupture, induced a rapid and significant increase in FSAP expression in monocytes, (n=88) after the intervention, remained elevated 72 h after symptom onset (n=80) and declined thereafter. A return to baseline levels was shown after 5 days (n=79), but it was still above the range of FSAP expression in monocytes on the day of symptom onset (n=130) (Figure 3A) .
Circulating monocytes in patients with ACS (UAP and AMI) (n=130) showed increased FSAP expression as compared with control non-coronary subjects (n=51) (Figure 3A) , but the differences were not significant. However, monocytes from patients with ACS expressed more FSAP after stimulation with lipopolysaccharide and tumor necrosis factor α as compared with control subjects (Figure 3B ).
Interaction Between FSAP Plasma Concentration and Cardiac Risk
To examine the interaction between FSAP plasma level and cardiac risk, the study population was dichotomized according to the calculated threshold level of 20.1 μg/ml for FSAP concentration and 1.035 PEU/ml for FSAP activity. Other than the higher concentrations of high-sensitivity C-reactive protein (hs-CRP) in patients with elevated FSAP plasma concentrations, the baseline characteristics of patients with an elevated FSAP were not significantly different from those of patients with a low FSAP plasma concentration ( Table 1) . With regard to FSAP activity (low <1.035 PEU/ml; high ≥1.035 PEU/ml) for the initial 24 h and 72 h periods (n=180), including periinterventional events, the combined endpoint of mortality and non-fatal myocardial infarction did not differ (P=0.69). For the 30-day and 6-month follow-ups, the difference in cardiac events between the groups was not statistically different. Dur- ing the 12-month follow-up (n=169), the event rate curves reached a level of statistical significance but continued to diverge, resulting in highly significant differences between groups after 12 months of follow-up (long-range P=0.023; Figure 4A ). The odds ratios for death and myocardial infarction was 1.895 (95% confidence interval [CI] 1.093-3.283; P=0.023) at 12 months. Kaplan-Meier analysis demonstrated that patients with high levels of FSAP activity had significantly higher probabilities of death or non-fatal myocardial infarction during a 1-year follow-up period. Examination of the association between high FSAP activity and cardiovascular events in the UAP and AMI groups without SAP patients also showed a poor prognostic power of FSAP activity level with an odds ratio of 10.7 (95% CI 8.072-13.328; P=0.048) for a higher event rate during the entire follow-up period of 1 year. However, it must be stressed that the number of cardiovascular events in each group was small, and larger series are needed to confirm whether the prognostic value of FSAP dif- FSAP mRNA levels in monocytes of ACS (UAP and AMI) and control groups were determined by real-time RT-PCR. Relative mRNA quantification was performed and the fold change in the target gene (FSAP), normalized to the internal control (GAPDH) and relative to the expression in the control group, was calculated and presented as a box/whisker plot. Significance was assumed at P<0.05. (B) FSAP mRNA expression in unstimulated and with lipopolysaccharide (LPS, 10 μg/ml) and tumor necrosis factor α (TNF-α: 20 ng/ml) stimulated peripheral blood monocytes supernatants after culturing for 20 h; 10 patients with ACS (blue bars) and 10 non-coronary artery disease subjects (green bars). Data are mean ± SEM. Significance was assumed at P≤0.05 vs. noncoronary artery disease subjects. AMI, acute myocardial infarction; UAP, unstable angina pectoris. FSAP in ACS fers between SAP and ACS (UAP and AMI). A stronger effect in patients with ACS would nevertheless be consistent with the fact that FSAP appears to be more expressed in atherosclerotic plaques of patients with UAP than in those with SAP.
FSAP concentration (low <20.1 μg/ml; high ≥20.1 μg/ml) for the combined endpoint of mortality and non-fatal myocardial infarction did not differ between groups (long-range P=0.562) for the whole period ( Figure 4B) . The odds ratio for death and myocardial infarction (adjusted for differences in baseline characteristics) was 1.17 (95% CI 0.69-1.98; P=0.562). In a stepwise multivariable logistic regression analysis including biochemical markers as well as baseline characteristics, none of the established risk factors for cardiovascular diseases was an independent predictor ( Table 2) . When FSAP plasma concentration was linked to traditional risk markers, bivariate correlation analysis revealed a significant correlation between FSAP and hs-CRP concentrations. Consequently, patients with high levels of FSAP activity had significantly higher CRP concentrations.
Discussion
The most significant observation from this study was that FSAP activity is increased in patients in the immediate aftermath of ACS. The data suggest that the activation of monocytes observed in ACS 9 is also associated with increased FSAP expression and this, together with activation of FSAP, may contribute to the pathogenesis of ACS. This suggestion is reflected by the lower survival of ACS patients with higher circulating FSAP concentrations in the present study. However, this marker adds only modest prognostic information to traditional risk factors, and was not specific to cardiovascular disease prediction.
In the present study, we measured the serial changes in plasma FSAP concentrations and activity after ACS (UAP and AMI). We found that higher levels of FSAP activity accompanied higher plasma FSAP concentrations in patients with ACS for up to 5 days. This is most likely to be because of a combination of increased expression from circulating monocytes and activation of FSAP by factors such as polyphosphates, polyamines, nucleic acids and nucleosomes released by necrotic heart tissue. 32, 33 In our results, plasma FSAP concentrations did not return to baseline levels for 5 days after AMI. These findings are similar to our recent observations that in multi-trauma patients there is a massive activation of FSAP, which returns to the baseline level after 48 h. 34 Some studies have reported that inflammatory markers, including interleukin-6 and CRP, are increased significantly in the acute phase of ACS, 35 and remain increased until a few weeks after myocardial infarction. FSAP antigen expression in monocytes is increased by interleukin-6 in vitro, 13 so this could be the reason for the sustained FSAP expression in monocytes. The occurrence of a local inflammatory state in patients with ACS is well established, as revealed by inflammatory markers such as CRP. 2, 3 Our regression analysis showed that as a marker of ACS, the serum concentration of hs-CRP remained significantly associated with the FSAP concentration in plasma from ACS patients, suggesting that FSAP is an additional marker and/or consequence of systemic inflammation.
We also calculated the values of plasma FSAP activity and concentration and examined the prognostic power of these at various time points after ACS (UAP and AMI) with respect to the frequency of cardiovascular clinical events, including nonfatal myocardial infarction or death. Kaplan-Meier analysis revealed that FSAP activity, but not FSAP concentration would be a predictor of cardiovascular events after ACS, indicating that increased FSAP activity during the 5 days after ACS might be associated with an increased likelihood of non-fatal myocardial infarction or death during the 1-year follow-up period. Thus, an increased FSAP plasma concentration is not only a marker of plaque instability, favoring the development of ACS, but more importantly it is highly predictive of the late clinical course after the onset of ACS before the occurrence of an acute ischemic event caused by plaque instability in the high-risk group of patients after ACS. Because we did not attempt to measure these FSAP values prospectively in asymptomatic patients and assess their development of ACS, we cannot comment on whether FSAP is indeed associated with or may actually be causative for the initial ACS event.
The progression and subsequent destabilization of atherosclerotic plaques involves major change in the structure of the arterial wall. 36, 37 Through its interactions with TFPI, factor VII as well as pro-urokinase FSAP also influences local coagulation and fibrinolysis. 10-12 FSAP is able to inhibit PDGF-BBmediated vascular SMC proliferation and migration 22 and neointima formation. 14 Inhibition of vascular SMC proliferation is, on the one hand, beneficial because it decreases neointimal mass, but on the other hand, it is harmful because a loss of vascular SMC results in thinning of the fibrous cap and results in increased plaque instability. 13,22 FSAP may be involved in processing the plaques' extracellular matrix, as well as inhibiting vascular SMC proliferation and, consequently, weakening the fibrous cap. This may result in a plaque morphology that is more susceptible to erosion, rupture, and subsequent thrombosis. Finally, we have recently demonstrated that activation of FSAP is linked to the generation of the anaphylatoxin C5a, which is also a prominent pro-inflammatory factor. 34 Through these different mechanisms, FSAP may be involved in the destabilization of the atherosclerotic plaque during ACS. The production of FSAP by activated cells within the atherosclerotic lesion and its release into the extracellular matrix appear to be strongly linked to the local inflammatory process occurring within the arterial wall. The present study demonstrates that a single FSAP measurement provides significant predictive value for the incidence of death and nonfatal myocardial infarction in a high-risk population of patients with ACS. Increased FSAP activity in plasma in patients with ACS was documented and it may serve as a marker of plaque destabilization.
